Era of direct acting anti-viral agents for the treatment of hepatitis C
Author:
Open Access
- 27 October 2018
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 10 (10) , 670-684
Abstract
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone. Now we have stepped into the era of direct acting anti-viral agents (DAAs) against hepatitis C virus. Treatment of hepatitis C is now extremely effective, tolerable and requires a short duration of intake of oral agents. Less monitoring is required with the current therapy and drug-drug interactions are less than the previous regimen. The current treatment options of chronic hepatitis C with various DAAs are discussed in this article. (c) The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.Keywords
This publication has 64 references indexed in Scilit:
- Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypesWorld Journal of Gastroenterology, 2016
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet, 2014
- Hepatitis C Virus NS3 Inhibitors: Current and Future PerspectivesBioMed Research International, 2013
- NS5A inhibitors in the treatment of hepatitis CJournal of Hepatology, 2013
- Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trialHepatology, 2012
- Pegylated interferon and ribavirin treatment for hepatitis C virus infectionTherapeutic Advances in Chronic Disease, 2010
- Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the TunnelViruses, 2010
- Hepatitis C Virus Population Dynamics During Infection2006
- Interferon for interferon naive patients with chronic hepatitis CCochrane Database of Systematic Reviews, 2002
- Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.Proceedings of the National Academy of Sciences, 1991